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Edited by Sandro SonninoAbstract To investigate a role for histidine residues in the
expression of normal acyl-CoA:cholesterol acyltransferase
(ACAT) activity, the histidine residues located at ﬁve diﬀerent
positions in two isoenzymes were substituted by alanine, based
on the sequence homology between ACAT1 and ACAT2. Among
the 10 mutants generated by baculovirus expression technology,
H386A–ACAT1, H460A–ACAT1, H360A–ACAT2, and
H399A–ACAT2 lost their enzymatic activity completely. A
reduction in catalytic activity is unlikely to result from structural
changes in the substrate-binding pocket, because their substrate-
binding aﬃnities were normal. However, the enzymatic activity
of H386A–ACAT1 was restored to <37% of the level of the
wild-type activity when cholesterol was replaced by 25-hydroxy-
cholesterol as substrate. H527A–ACAT1 and H501A–ACAT2,
termed carboxyl end mutants, exhibit activities of 96% and
75% of that of the wild-type. Interestingly, H425A–ACAT1
showed 59% of the wild-type activity, in contrast to its equivalent
mutant, H399A-ACAT2. These results demonstrate that the his-
tidine residues located at the active site are very crucial both for
the catalytic activity of the enzyme and for distinguishing
ACAT1 from ACAT2 with respect to enzyme catalysis and sub-
strate speciﬁcity.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Acyl-CoA:cholesterol acyltransferase (ACAT; EC 2.3.1.26),
a multimembrane-spanning protein, plays an important role in
the esteriﬁcation of cholesterol with its substrates, cholesterol
and fatty acyl coenzyme A (CoA) [1], to facilitate both intra-*Corresponding author. Fax: +82 42 861 2675.
E-mail address: tsjeong@kribb.re.kr (T.-S. Jeong).
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doi:10.1016/j.febslet.2006.04.035cellular storage [2] and intercellular transport [3]. The mamma-
lian ACAT exists as two isoenzymes, which are quite diﬀerent
with regard to chromosomal locations of their genes [4], tissue-
speciﬁc expression [5], and substrate speciﬁcity [6,7]. It is
generally accepted that both isoenzymes are inhibited simulta-
neously to exert the maximum therapeutic eﬀect against hyper-
cholesterolemia and atherosclerosis. On the basis of this
concept, an isotype-speciﬁc inhibitor screening system has
been established for the recombinant ACAT1 and ACAT2
by our laboratory [8] and by Rudel’s group [9].
Previously [8], we reported cloning and overexpression of
cDNAs of each isoenzyme (Accession No. BC028940 and
AF059203 for ACAT1 and ACAT2, respectively) using the
baculovirus expression system. Analysis of the sequences re-
vealed that 12 and 14 histidine residues are present in ACAT1
and ACAT2, respectively, and some of them have similar loca-
tions in the highly conserved sequences that are adjacent to the
particular motifs (Fig. 1). Although the two sequences have a
level of homology of <55% [10], the location of some histidine
residues in both isoenzymes is highly conserved. Histidine res-
idues are frequently involved in enzymatic catalysis due to the
reactive imidazolium nitrogen atom, which functions as a
hydrogen bond donor/acceptor. Recently, it has been reported
that histidine residues located in the long hydrophobic region
of H460A–ACAT1 [11] and H434A–ACAT2 [12] play a signif-
icant role for ACAT catalysis. Similarly, His377 at the active
site of lecithin:cholesterol acyltransferase (LCAT), another en-
zyme involved in cholesterol esteriﬁcation, is critical for LCAT
activity [13], suggesting that histidine might have an important
role in the cholesterol esteriﬁcation reaction. In this regard,
ﬁve histidine residues from each ACAT isoenzymes, including
H460A–ACAT1 and H434A–ACAT2, were selected on the ba-
sis of the sequence similarity between the two isoenzymes. For
example, the histidine residues of both H386–ACAT1 and
H360–ACAT2 are located exactly 17 residues from the
FYxDWWN motif [10] toward each N terminus. Similarly,
the histidine residues of both H425–ACAT1 and H399–
ACAT2 are located exactly 16 residues away from the
FYxDWWN motif toward each C terminus. Thus, we antici-
pate that the histidine replacement study could identify critical
histidine residues at speciﬁc locations for the ACAT enzyme
reaction, and consequently help to elucidate the catalyticblished by Elsevier B.V. All rights reserved.
hACAT1 MVGEEKMS LRNRLSKSRENPEEDEDQRNPAK ES LETPSNGRI DI KQL IAK K I K LTAEAEELKP FFMKEVGSH FDDFVTNL  80
hACAT2 ~~~MEPGGARLRLQRTEGLGGERE----RQPCGDG--NTETHRAPDLVQWTRHMEAVKAQLLEQAQGQLREL-------LDRAMREA  71
hACAT1 IEKSAS LDNGGCALTTFSVLEGEKNNHRAKDLRAPPEQGKI FIARRSLLDELLEVDH I RTIYHMFIALL I LFILSTLVVD  160 
hACAT2 IQSYPSQD------------------KPLPPPPPGS LSRTQEPSLGKQKVFI IRKSLLDELMEVQHFRTIYHMFIAGLCVFIISTLAI D   142
hACAT1 YIDEGRLVLEFSLLSYAFGKFPTVVWTWWIMFLSTFSVPYFLFQHWATGYS KSSHPLIRSLFHGFL FMIFQIGVLGFGPT  240
hACAT2 FIDEGRLLLEFDLLI FS FGQLPLALV TWVPMFLSTLLAPYQALRLWARGTWTQATGL-----------GCALLAAHAVVLCALPV  216
hACAT1 YVV LAYTLPPASRF I I I FEQ IRFVMKAHSFVRENVPRVLNSAKEKSSTVP IPTVNQYLYFLFAPTLIYRDSYPRNPTVRW  320
hACAT2 HVAVEHQLPPASRCVLVFEQVRFLMKSYSFLREAVPGTLRA - - RRGEGIQAPSFSSYLYFLFCPTLIYRETYPRTPYVRW  294
hACAT1 GYVAMKFAQVFGCFFYVYYIFERLCAPLFRN IKQEPFSARVLVLCVFNSILPGVLILFLTFFAFLHCWLNAFAEMLRFGD 400
hACAT2 NYVAKNFAQALGCVLYACFILGRLCVPVFANMSREPFSTRALVLSI LHATLPGIFMLLLIFFAFLHCWLNAFAEMLRFGD 374
hACAT1 RMFYKDWWNSTSYSNYYRTWNVVVHDWLYYYAYKD FLWFFSKRFKSAAMLAVFAVSAVVHEYALAVCLSFFYPVLFVLFM  480
hACAT2 RMFYRDWWNSTSFSNYYRTWNVVVHDWLYSYVYQDGLRLLGARARGVAMLGVFLVSAVAHEYI FCFVLGFFYPVMLI LFL   454
hACAT1 FFGMAFNF I V NDSRKKP IWNVLM WTSLFLGNGVLLCFYSQEWYARQHCPLKNPTFLDY VRPRSWTCRYVF  550 
hACAT2 VI GGMLNFMMHDQRTGPAWNVLMWTMLFLGQGIQVSLYCQEWYARRHCPLPQATFWGLVTPRSWSCHT~~ 522
Fig. 1. Comparison of sequence homology in highly conserved regions where the speciﬁc mutated positions are located. Sequences of ACAT1 and
ACAT2 shown here are from the GenBank database (Accession Nos. BC028940 for ACAT1 and AF059203 for ACAT2). Histidine residues selected
for the point mutation are shown in bold and adjacent amino acid residues in the highly conserved region are underlined. The putative motifs [10],
MK . . .SF and FYxDWWN are indicated by blue and red characters, respectively.
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ACAT2.2. Materials and methods
2.1. Mutagenesis and protein expression
Each of the mutant cDNAs was generated by a Pfu polymerase
chain reaction-based, site-directed mutagenesis kit (Stratagene), using
appropriately designed oligonucleotide primers with template cDNA
in pBlueScript II. For mutant veriﬁcation, primers were designed for
each mutant containing diﬀerent endonuclease sites with original tem-
plate. For ACAT1 mutants, the following primers were used:
H137A, 5 0-ggcgctctctcttagatgaacttctagaagtggacgccatcagaac-3 0;
H386A, 5 0-ctttttttgcctttttggcctgctggctcaatgcctttgctgag-30;
H425A, 5 0-gaacctggaatgtggtggtcgctgactggctatattactatgc-3 0;
H460A, 5 0-gctgtatctgcagtagtagccgaatatgccttggctgtttgcttg-30;
H527A, 5 0-ctcaagaatggtatgcccgtcaggcttgtcctctgaaaaatcccac-3 0.
For ACAT2 mutants, the following primers were used:
H119A, 5 0-gagctgatggaggtgcaagctttccgcaccatctaccacatg-30;
H360A, 5 0-gctgctgctaatattctttgccttcctcgcttgctggctcaacgc-3 0;
H399A, 5 0-ctactaccgtacgtggaacgtggtggtcgctgactggctgtacag-3 0;
H434A, 5 0-gttcctggtgtccgcagtggccgctgagtatatcttctgc-30;
H501A, 5 0-gagtggtacgcccggcgggcctgccccttacc-3 0.
The mutated full-length cDNA was veriﬁed by examining the
cleavage pattern of cDNA by endonuclease, conﬁrmed by DNA
sequencing, and ligated into pBlueHisBac2A vector (Invitrogen) after
appropriate endonuclease digestion. Recombinant baculovirus for the
mutants was generated using a MaxBac 2.0 kit (Invitrogen). The
clones puriﬁed by plaque assay were ampliﬁed until at least 1 · 107
plaque-forming units (pfu) were obtained. The presence of recombi-
nant virus was proved by polymerase chain reaction analysis of viral
DNA in every step of generation of the recombinant virus according
to the manufacturer’s protocols. Protein expression was carried out
according to our previous report, using Hi5 cells [8], with treatment
of the same amount of recombinant virus (multiplicity of infec-
tion = 1).2.2. Preparation of the microsomal fraction and the enzyme assay
Disruption of insect cells and recovery of cell lysate microsomal frac-
tions [14] containing recombinant ACAT mutants were carried out as
described [8,15]. To determine the ACAT enzymatic activity of the
microsomal fractions, two methods were employed using diﬀerent radi-
olabeled substrates. In assay method 1, [1-14C]oleoyl-CoA (56 lCi/lmol; Amersham Biosciences, UK) was used as a tracer of newly
formed cholesteryl ester (CE), as described [14]. In assay method 2,
[4-14C]cholesterol (50 lCi/lmol; Amersham Biosciences, UK) was
added to the assay as an indicator of CE products as described [16].
Brieﬂy, a reaction mixture of 100 ll total volume was prepared, con-
taining 4 ll of microsomal fraction (8 mg/ml of protein), 81 ll of sub-
strates (ﬁnal concentration of 100 lM oleoyl-CoA (Sigma O-1012) and
1 mM cholesterol (mixture of unlabeled cholesterol:labeled cholesterol,
100:1)), and 15 ll of bovine serum albumin (fatty acid-free, 40 mg/ml).
Esteriﬁcation of cholesterol was allowed to proceed for 30 min and
stopped by the addition of 2 ml of organic quencher (chloroform/meth-
anol, 2:1, v/v) that contained internal standards, ﬁnal concentrations of
5 mg/ml of free cholesterol (FC) and 2.5 mg/ml of CE. Esteriﬁed prod-
ucts were isolated by sequential extraction with organic solvent and
separated on thin-layer chromatography plates (Gelman Sciences
51432) using a solvent system of petroleum ether/diethyl ether/acetic
acid (90:10:1, by vol.). The separated FC and CE bands were visualized
by staining with iodine vapor and the radioactive content of the excised
bands of FC and CE was determined by scintillation counting. The
enzymatic activity of ACAT proteins was normalized to the expression
level determined by Western blot analysis.2.3. Substrate-binding assay
The substrate-binding capacity of wild-type ACAT (WT-ACAT)
and their mutants, adjusted to possess the same expression unit, was
determined by a ﬁltration method as described [17,18] using glass-ﬁber
ﬁlters (2.5 cm, GF/C; Whatman) soaked in 0.5% (w/v) polyethyleni-
mine. Saturation binding experiments were performed in 500 ll of en-
zyme assay buﬀer, using 50–100 lg of protein per tube and
[1-14C]oleoyl-CoA or [4-14C]cholesterol, ranging between 10 and
80 lM, incubated at 37 C for 2 h, by which time the radiolabeled sub-
strate had reached equilibrium. Each experiment was performed in
triplicate. Reaction aliquots (typically 300 ll) were applied to the ﬁlters
in the absence of vacuum to achieve a uniform spread of the suspen-
sion over the ﬁlter surface, then vacuum was applied, and the ﬁlters
were washed with 10 ml of ice-cold phosphate-buﬀered saline
(140 mMNaCl, 10 mMKCl, 1.5 mM KH2PO4, and 8 mM Na2HPO4).
Competition binding experiments were performed with 10 lM
[1-14C]oleoyl-CoA or 40 lM [4-14C]cholesterol in the presence of
increasing concentrations of non-labeled oleoyl-CoA or cholesterol.2.4. Inhibition assay
The inhibitory sensitivity of activity-retaining mutants H425A and
H527A of ACAT1 and H501A of ACAT2 toward known ACAT
inhibitors, such as oleic acid anilide [8], pyripyropene A [8], 3-(3,
S. An et al. / FEBS Letters 580 (2006) 2741–2749 27435-di-tert-butyl-4-hydroxyphenyl)-5-(3,5-di-tert-butyl-4-hydroxyphenyl)-4,
5-dihydropyrazoline (pyrazoline) [19], and linoleic amide [20] was
determined. The inhibitory assay was carried out using microsomal
fractions of ACAT isoenzymes and their mutants with substrates
[1-14C]oleoyl-CoA and cholesterol as described [8].
2.5. Western blot analysis
Monoclonal antibody that was raised against the N-terminal fraction
of either ACAT1 or ACAT2 (Vancouver Biotech, Canada) and poly-
clonal antibody against the His-probe (Santa-Cruz Biotechnology, cat
# sc-8036) were used to detect the N-terminal region of proteins. Since
ACAT2 has a 10-amino acid c-myc tag at the C-terminal region, c-Myc
(9E10) antibody (Santa-Cruz Biotechnology, cat # sc-40) was used to
detect the C-terminal region of ACAT2. The intensity of the detected
bands was scanned and compared using a Calibrated Densitometer
GS800 (BioRad, Hercules, CA) with Quantity One software (version
4.4.0). The band intensity was considered as reﬂecting the expression
level of individual mutants and was used to normalize each enzyme
activity and to adjust the proteins to have the same expression unit.3. Results
3.1. Relative expression levels of the recombinant proteins
The relative expression level of each mutant was determined
by Western blotting analysis as shown in Fig. 2. Detection of
the N-terminal region of ACAT1 revealed that the expression
level of the mutants was similar to that of the wild-type, except
H386A, which exhibits an almost 2-fold increase compared to
the wild-type. Among the ACAT2 mutants tested, the expres-
sion of H360A was found to be 1.5-fold higher than that of the
wild-type in both N- and C-terminal detection, while H399A
resulted in the least yield. In the case of H501A, the expression
level was varied, depending on the antibody. We speculate that
substitution of histidine by alanine at position 501 might have
induced structural change in the C-terminal region, resulting in
a decrease of antigenicity. The band intensity of each mutant
detected by His antibody was used to normalize its enzymeFig. 2. Determination of the level of protein expression by immuno-
blot analysis. Band intensity was compared as shown at the bottom of
the gel.activity. Interestingly, H137A–ACAT1, H119A–ACAT2, and
H434A–ACAT2 were not detected immunologically, despite
the fact that production of recombinant baculovirus was evi-
dent. This result can be interpreted in two ways. First, these
mutants might not exist, owing to protein instability. Second,
the single replacement at position 137 (ACAT1) or at positions
119 and 434 (ACAT2) by alanine might have provoked com-
plete loss of antigenicity. Under the same assumption, ACAT1
and ACAT2 might have diﬀerent transmembrane domain
arrangements in the vicinity of H460 and H434, because
H460A–ACAT1, the equivalent mutant of H434A–ACAT2,
was detected by Western blot analysis.3.2. Enzyme activity of histidine mutants
The H386A and H460A mutants exhibited very low activi-
ties, similar to the background level, while the H527A mutant
appeared to possess about 96% of the activity of the wild-type
ACAT1 (WT-ACAT1) (Fig. 3A and C). Among the ACAT2
mutants, most had activities of <12% that of the wild-type, ex-
cept H501A, which showed the highest level of activity, 75% of
that of the wild-type (Fig. 3B and D). The enzyme assays using
[1-14C]oleoyl-CoA and cholesterol (Fig. 3A and B) as well as
[4-14C]cholesterol and oleoyl-CoA (Fig. 3C and D) as sub-
strates showed similar results. These results suggest that
H386 and H460 derived from ACAT1, and H360 and H399
derived from ACAT2, appear to be crucial in ACAT activity,
but the carboxy-terminal histidine residue does not seem to be
important for full activity in these isoenzymes. H425A–
ACAT1 maintained considerable activity, 60% of that of
the wild-type, in contrast to its equivalent mutant, H399A–
ACAT2, which nearly lost its activity as an ACAT enzyme.
The results indicate that these histidine residues located 16 res-
idues away from the FYxDWWN motif toward each C termi-
nus might be at the very core of the region that induces
diﬀerences in the catalytic mechanism between ACAT1 and
ACAT2. In addition, H137A–ACAT1, H119A–ACAT2 and
H434A–ACAT2, which were not immuno-detected, showed
no detectable activity in any assay method (data not shown).
We next determined the enzymatic activity of each mutant
against 25-hydroxycholesterol, which is utilized more eﬃ-
ciently in ACAT2 catalysis (Fig. 3E and F), and found that
H386A–ACAT1 restores enzymatic activity of <37% of that
of wild-type activity, while it showed a basal level of activity
against cholesterol. From this result, H386 might be suggested
to be an important reaction assistant involved in the substrate
speciﬁcity of ACAT1, which utilizes cholesterol more eﬃ-
ciently than 25-hydroxycholesterol.3.3. Substrate-binding activity of the histidine mutants
To further investigate whether the loss of ACAT activity in
histidine mutants stems from an improper substrate embed-
ding into the membrane or inadequate protein folding, we as-
sessed the binding activity of each mutant against
[1-14C]oleoyl-CoA and [4-14C]cholesterol, and certiﬁed binding
speciﬁcity through binding competition (inset graphs). As
shown in Fig. 4, all of the histidine mutants retained a substan-
tial part of the [1-14C]oleoyl-CoA binding activity of the WT-
ACAT; for example, even H460A–ACAT1 (Fig. 4A) and
H360A–ACAT2 (Fig. 4B), which had the lowest binding activ-
ity, displayed around 75% and 85% of the wild-type activity,
respectively. There might be a relationship to a minor degree
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Fig. 3. Relative enzymatic activity of the recombinant proteins of point mutations. For enzyme assay method 1, 10 lM [1-14C]oleoyl-CoA (0.05 lCi)
and 10 lM cholesterol (A and B) or 25-hydroxycholesterol (E and F) were used to trace cholesteryl oleate, a product of the enzyme reaction. For
enzyme assay method 2, 1 mM [4-14C]cholesterol (0.05 lCi) and 100 lM oleoyl-CoA were used as described in Section 2 (C and D). The data are
normalized by expression level and shown as the means ± S.D. from three independent experiments performed in duplicate. Statistically signiﬁcant
diﬀerence in activity compared to WT-ACAT: ***P < 0.00001, **P < 0.001, *P < 0.05.
2744 S. An et al. / FEBS Letters 580 (2006) 2741–2749between enzymatic activity and oleoyl-CoA binding activity on
the basis of results indicating that the upward order of enzy-
matic activity and oleoyl-CoA binding activity is consistent,
but the degree is too small to impact full ACAT activity. These
invariant substrate-binding characteristics of histidine mutants
are seen more clearly in the [4-14C]cholesterol binding assay,
where the cholesterol-binding capability of all histidine mu-
tants and the WT-ACAT was almost the same (Fig. 4C and
D). The ﬁndings based on the substrate-binding assay led us
to conclude that alanine substitution of a histidine residue
did not seem to induce inadequate protein folding or substrate
embedding, and that H386A and H460A of ACAT1, andH360A and H399A of ACAT2 nulliﬁed the ACAT enzymatic
activity mainly via obstruction of the catalytic process.
3.4. Inhibitory sensitivity of the ACAT mutants
To test the inhibitory sensitivity of ACAT isoenzymes and
their activity-retaining mutants, H425A and H527A of
ACAT1, and H501A of ACAT2, known ACAT inhibitors,
were used in the enzyme assay. The known ACAT inhibitors
caused a reduction of the activity of WT-ACAT1 and WT-
ACAT2 isoenzymes, with IC50 values of 0.14 and 0.17 lM
for oleic acid anilide, of 2.9 mM and 0.98 lM for pyripyropene
A (ACAT2-speciﬁc inhibitor), of 22.1 and 73.6 lM for
[14C]cholesterol (μM)
10-1 100 101 102
0
500
1000
[14C]cholesterol (μM)
10-1 100 101 102
0
500
1000
[14C]oleoyl-CoA (μM)
10-1 100 101
0
500
1000
1500
WT-ACAT1
A1-H386A
A1-H425A
A1-H460A
A1-H527A
[14C]oleoyl-CoA (μM)
10-1 100 101
0
500
1000
1500
WT-ACAT2
A2-H360A
A2-H399A
A2-H501A
Non-labeled oleoyl-CoA (μM)
10-410-1 100 101 102
500
1000
1500 B
Non-labeled oleoyl-CoA (μM)
10-410-1 100 101 102
0
500
1000
Non-labeled cholesterol (μM)
10-4 100 101 102 103
0
500
1000
1500
Non-labeled cholesterol (μM)
10-4 100 101 102 103
0
500
1000
ACAT-1 ACAT-2
A
DC
[14
C]
ole
oy
l-C
oA
 bi
nd
ing
 (C
PM
 x 
10
-
2 )
[14
C]
ch
ole
ste
ro
l b
ind
ing
 (C
PM
 x 
10
-
3 )
Fig. 4. Eﬀects of histidine mutations of ACAT on the binding activity of [1-14C]oleoyl-CoA (A and B) and [4-14C]cholesterol (C and D). Substrate-
binding activity was measured with the same expression unit of each ACAT protein as described in Section 2. The binding speciﬁcity was determined
by competition assay using non-labeled oleoyl-CoA or cholesterol (inset) as competitor. Results are representative of two independent experiments
performed in triplicate.
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respectively (Fig. 5). The inhibitory eﬀects of pyrazoline and
linoleic amide were very similar between each ACAT isoen-
zyme and its mutants (Fig. 5C and D). However, the inhibitory
sensitivity against oleic acid anilide was decreased in H527A–
ACAT1 (IC50 = 3.1 lM) and H501A–ACAT2 (IC50 = 1.9 lM)
about 10-fold, and in H425A–ACAT1 (IC50 = 0.46 lM) about
3-fold (Fig. 5A) compared to the WT-ACAT isoenzyme. In the
case of pyripyropene A, H425A–ACAT1 (IC50 = 96.8 lM) and
H527A–ACAT1 (IC50 = 136.4 lM) were inhibited fairly well,
while the WT-ACAT1 showed resistance to inhibition until
the millimolar level, and H501A–ACAT2 was inhibited to a
degree similar to that of the WT-ACAT2 (Fig. 5B). This means
that pyripyropene A in H425A–ACAT1 and H527A–ACAT1
results in considerable loss of the inhibition property as an
ACAT2-speciﬁc inhibitor. These results show that the alanine
substitution in H425 and H527 of ACAT1 and H501 of
ACAT2 result in decrement or increment of the inhibition
capability of ACAT as an inhibitor and induce diminution
of ACAT isotype-speciﬁc inhibition.
4. Discussion
It has been reported that the two ACAT isoenzymes have
diﬀerent transmembrane domain structure and catalytic core,corresponding to their diﬀerent physiological roles and tis-
sue-speciﬁc expression. In addition to these diﬀerences,
ACAT1 and ACAT2 have diﬀerent substrate speciﬁcity; such
that cholesterol is superior to 7-ketocholesterol or 7a-hydrox-
ycholesterol as an allosteric activator for ACAT1 [7], while 25-
hydroxycholesterol is utilized more eﬃciently by ACAT2 than
by ACAT1 [8]. The crystal structure of ACAT has not been
determined, owing to the diﬃculty of puriﬁcation, and current
research of ACAT is limited to cell biology and related ﬁelds of
study. The mechanism of the ACAT catalytic reaction remains
to be elucidated, in spite of a few transmembrane domain
(TMD) models proposed by various groups [21,22]. According
to Chang et al., residues H386 and H460 of ACAT1 are lo-
cated in the middle of the membrane, while H137, H425,
and H527 are located in the cytoplasm and ER lumen, respec-
tively (Fig. 6A) [11]. In the case of ACAT2, nearly all of the
histidine residues exist in the cytoplasm, except H434, which
is present within the membrane (Fig. 6B) [12].
Multiple alignment of a conserved region in the membrane-
bound O-acyltransferase family, including ACAT1, ACAT2,
DGAT, and 20 other enzymes, revealed that H460–ACAT1
and H434–ACAT2 are an invariant histidine residue [23].
Chang et al. proposed that the putative ACAT catalytic do-
main, VFAVSAVVHEY for ACAT1, which includes H460
[22], VFLVSAVAHEY for ACAT2, which includes H434
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Fig. 5. Inhibitory sensitivity of four ACAT inhibitors, oleic acid anilide (A), pyripyropene A (B), pyrazoline (C), and linoleic amide (D) against WT-
ACAT1 and WT-ACAT2 and their mutants exhibiting enzymatic activity. The enzyme sources used were as described in Fig. 4. IC50 values of each
protein against each inhibitor are shown in parentheses. Data are presented as the means ± S.D. from three independent experiments performed in
duplicate.
2746 S. An et al. / FEBS Letters 580 (2006) 2741–2749[12], is located within a phospholipid bilayer, enabling the en-
zyme to produce CE in the same membrane, and recently con-
ﬁrmed that H460 located in TMD7 is a key active site residueof ACAT1 [11]. The complete loss of ACAT activity of
H460A–ACAT1 in the studies described here is in good agree-
ment with previous results and with the transmembrane do-
Fig. 6. The topological position of histidine residues substituted by alanine in this study. The histidine residues are depicted in the ACAT
transmembrane topology model with nine TMDs for hACAT1 [11] and two TMDs for hACAT2 [12]. The MK . . .SF and FYxDWWN motifs [10]
are identiﬁed by green boxes and blue boxes, respectively.
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H460A–ACAT1, was not immuno-detected in our data. This
phenomenon is similar to the result presented by Lin et al. that
ACAT1 with an HA tag on the residue at position at 459 was
not detected by DM10 antibody raised against the N terminus
of ACAT1 [24]. We discovered that H386 of ACAT1, and
H360 and H399 of ACAT2 are critical residues involved in
ACAT catalysis. After showing that H386A and H460A of
ACAT1 impair enzymatic activity, we paid attention to the
currently reported topology model [11], where both residues
are located in the middle of the membrane, as shown in
Fig. 6A. This interpretation supports the suggestion that catal-
ysis of ACAT, especially ACAT1, is accomplished in the mem-
brane bilayer. It is conceivable that H386, positioned on the
cytoplasmic side of the ER membrane, is located close to the
biding site for the 25th carbon atom of cholesterol and facili-
tates the transfer of cholesterol in preference to 25-hydroxy-
cholesterol into the catalytic core in the enzyme reaction
process. We arrived at this conclusion on the basis that
H386A recovered enzyme activity against 25-hydroxycholes-
terol up to 37% of that of the wild-type, whereas H460A did
not. If H386 acts in the catalytic reaction, no matter what
the substrate, its activity would be lost completely.
Our data show consistently that H360 and H399 of ACAT2
play a signiﬁcant role in catalysis. Regarding the topology
model for ACAT2 [12], H360 and H399 are located in the
cytoplasm, while H434 is on the cytoplasmic side of the ER
membrane, as shown in Fig. 6B. Therefore, it is possible to ex-plain why catalysis in the plane of membrane is limited in
ACAT1 and that catalysis of ACAT2 takes place in the cyto-
plasm or near the cytoplasmic side of the membrane. Although
this is a reasonable induction, the possibility still exists that
H360, which is immediately outside of the ﬁfth transmembrane
segment, is in the membrane, and that under the same assump-
tion, the topological positioning of H399 could be changed as
the topology model is developed.
To our surprise, H425A–ACAT1 still contained a signiﬁcant
amount of residual enzyme activity, whereas its equivalent mu-
tant of ACAT2, H399A, caused total loss of activity. These re-
sults raise the possibility that these histidine residues,
positioned 16 residues away from the FYxDWWN motif [10]
toward each C terminus, are at the very core of the region that
induces diﬀerences in the catalytic mechanism between
ACAT1 and ACAT2.
It is interesting to note that the enzymes that bind choles-
terol substrates, i.e. serine esterase, ACAT, and LCAT, possess
serine, histidine, and aspartic acid residues in the active site as
a catalytic triad [25–27]. Histidine residues are frequently
found in general acid-base catalysis [28,29], reaction intermedi-
ate stabilization [30–32] through hydrogen bonding of their
NE2 nitrogen atom. Recently, the X-ray structure has been
determined of OMPLA [33], an integral membrane enzyme,
where the active center is located in the outer leaﬂet of the
membrane and contains a histidine residue as part of the cat-
alytic triad [34]. Another structural study of 3beta-hydroxy-
steroid dehydrogenase (3bHSD) isoenzymes demonstrated
2748 S. An et al. / FEBS Letters 580 (2006) 2741–2749that His156 of 3bHSD1 interacts with the 3b-hydroxyl group
of the steroid substrate with 14-fold higher aﬃnity compared
with 3bHSD2 containing Tyr156 [35]. Substrate binding is
not impaired substantially in all histidine mutants and, on
the basis of this feature, it is likely that critical histidine resi-
dues of ACAT isoenzymes are not involved in the stabilization
of the transition-state intermediate. To put these consider-
ations together, H386 and H460 of ACAT1, and H360 and
H399 of ACAT2 may function as general bases, interacting
with the 3b-hydroxyl group of cholesterol in the hydrophobic
membrane bilayer or near the membrane and therefore impact
on the catalytic activity of ACAT.
In addition, we observed that the single amino acid substitu-
tion of H425 and H527 of ACAT1, and H501 of ACAT2 can
induce a decrement or increment of the inhibition capability of
the ACAT inhibitor and diminution of ACAT isotype-speciﬁc
inhibition. This result suggests that there is a speciﬁc inhibitor
response to even a tiny structural alteration of ACAT, and this
explanation supports the possibility of ﬁne modulation by a
speciﬁc inhibitor. Therefore, structure-based study of the orga-
nization of the catalytic core will facilitate the development of
a speciﬁc ACAT inhibitor.
In summary, we revealed that H360 and H399, cytoplasmic
histidine residues, are essential for catalysis of ACAT2,
whereas H386, the critical histidine residue of ACAT1, is posi-
tioned in the hydrophobic membrane in the same way as H460,
which has been reported as a member of the catalytic triad.
This leads to the hypothesis that catalysis of ACAT1 occurs
in the plane of the membrane. Further to this, we found that
H425 of ACAT1 is not crucial for full activity of the enzyme,
in contrast to its equivalent mutant, H399 of ACAT2. These
interpretations imply that there is a diﬀerent catalytic mecha-
nism between ACAT isoenzymes, where several histidine resi-
dues are involved. On the basis of the results presented here,
further research including structure determination by X-ray
crystallography is needed to determine the precise catalytic
site. The knowledge gained from the results of these mutagen-
esis studies will be valuable in directing the active site modeling
of ACAT isoenzymes and the design of ACAT1 or ACAT2
speciﬁc inhibitors.
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